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products where more brands were available. The larger the brand premium, then the 
lower the market share of the premium brand. More multiple switchers were aged 
under 50 years (31%) than 70–79 years (20%). CONCLUSIONS: Multiple switches 
between SSRI brands occur in around one in four Australian Concessional patients 
and this has the potential to confuse some patients if not adequately monitored by 
prescribers and pharmacists. Switching rates increased where more brands are avail-
able on the PBS as well as in younger patients. 
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PHYSICIAN PRESCRIBING PATTERNS IN INNOVATIVE 
ANTIDEPRESSANTS IN THE UNITED STATES: THE CASE OF PATIENTS 
WITH MAJOR DEPRESSIVE DISORDER
Lin HC, Balkrishnan R
University of Michigan, Ann Arbor, MI, USA
OBJECTIVES: The use of innovative antidepressants has been growing as many were 
introduced since 1990s. However, physician prescribing patterns in innovative antide-
pressants is unclear. This study disentangled the impacts of sociological factors, such as 
physician, patient, and health-care system factors, on the patterns and dynamics of 
adopting innovative antidepressants for major depressive disorder (MDD) in the US. 
METHODS: A retrospective 15-year cross-sectional study was conducted using the 
1993–2007 National Ambulatory Medical Care Survey representing 125,605,444 MDD 
patients. The Heckman two-step model was used to capture physician’s two-stage 
prescribing decision and to correct sample selection bias. First, logistic regression was 
applied to examine the impact of sociological factors on whether an antidepressant is 
prescribed. Second, multinomial logistic regression was used to capture physician choices 
of innovative versus.older antidepressants. RESULTS: A total of 71.22% MDD patients 
were prescribed an antidepressant. Physicians who were primary care physicians, non-
owner of health-care settings, practiced in Western and non-metropolitan areas, and 
had not seen patients before were more likely to prescribe innovative antidepressants 
(all P < 0.001. ) Patients who were younger, non-Hispanic, belong to HMOs, and took 
patient education were more likely to receive innovative antidepressants (all P < 0.001.) 
Trend analyses revealed that physicians who were owners of non-solo practice, practiced 
in Midwestern, Northeastern and metropolitan areas were decreasing likelihood of 
prescribing innovative antidepressants over time. Patients who were non-white, non-
black and non-Hispanic, and enrolled in Medicaid had increasing likelihood of receiving 
innovative antidepressants over time. CONCLUSIONS: The patterns of physician pre-
scribing innovative antidepressants for MDD patients in the United States varied with 
sociological factors. Patient characteristics, physicians characteristics, and health-care 
system factors had impacts on physician’s decision on choosing innovative antidepres-
sants. Prescribing patterns also varied over time. 
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HEALTH SCIENCE STUDENTS ATTITUDES TOWARD RESEARCH AND 
IT’S IMPLICATIONS TO TEACHING
Mayya SS
Manipal University, Manipal, Karnataka, India
OBJECTIVES: To assess the attitudes toward research of health science students and 
discuss its implications to teaching. Attitudes about research are important because they 
may inﬂ uence the quality of research. In particular, attitudes and beliefs about research 
can affect the extent to which they will develop useful critical thinking skills. Health 
science students usually tend to view research methods courses negatively. However, an 
understanding of these attitudes is necessary to help instructors facilitate the learning of 
research methodology, by enabling them to create more positive attitudes toward such 
courses. METHODS: The attitudes toward research of students of health sciences (n = 
79), Manipal University, were measured using the instrument: the Attitudes toward 
research scale –ATR (Papanasiou, 2005). The sample of the study consisted of students 
enrolled for a course on “Biostatistics, Research Methodology and Epidemiology.” The 
ATR consist of 32 items constituting ﬁ ve subscales: research usefulness, research anxiety, 
positive attitudes, relevance to life, difﬁ culty of research. Data was summarized by 
computing descriptive statistics. RESULTS: Students of health sciences scored more than 
70% of the maximum score on the subscales -research usefulness, positive attitudes and 
relevance to life. They scored less than 50% of the maximum score on subscales 
-research anxiety and difﬁ culty of research. Students expressed that estimating sample 
size, data analysis and interpretation are the most difﬁ cult aspects in research. CON-
CLUSIONS: To reduce the research anxiety and feeling of difﬁ culty, topics relating to 
statistics are to be taught in a simpler way. They should be provided practical experience 
through project work. Usefulness of the topics is to be emphasised through actual data 
analysis and interpretation relating to their ﬁ eld. 
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THE LONG-TERM UTILIZATION AND SAFETY OF BIOLOGICAL 
AGENTS IN TREATING RHEUMATOID ARTHRITIS PATIENTS—A 
POPULATION-BASED CASE STUDY IN SOUTHERN TAIWAN
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OBJECTIVES: This case study aims to evaluate the long-term utilization and safety 
of two biological agents- etanercept and adalimumab in treating Taiwanese rheuma-
toid arthritis (RA) patients. METHODS: This cohort study used a population-based 
claim-data from the Kaopin Division of Taiwanese National Health Insurance during 
March 2006 to June 2009. Adult RA outpatients were identiﬁ ed by diagnosis code, 
and followed from the ﬁ rst prescription date (index date) of biological agents up to 
two months after discontinuation (prescription stop for more than 30 days) or the 
end of study. Prescription continuation rate between two drugs was evaluated using 
Kaplane-Meier survival curves and compared by the log-rank test. The frequencies of 
infectious events for new users of biological agents were also collected and the odds 
ratios of infectious events comparing etanercept against adalimumab were evaluated 
by logistic regression. RESULTS: Of all, 190 new users (mean age 53.43 ± 11.61 years; 
83.68% female) were assessed. Most patients (70.53%) were prescribed biological 
agents in medical centers and 63.16% of them used etanercept. Total cumulative 
exposure time is 184.32 patient-years (145.86 patient-years in etanercept group, 38.46 
patient-years in adalimumab group). Overall continuation rate for biological agents 
is 78.06% after 1 year, 55.04% after 2 years. The median continuation time is 836 
days (95% CI 541, 972). Twenty-nine infectious events were detected; the most fre-
quent events are pneumonia (seven events) and tuberculosis (six events). Patients who 
treated by etanercept had more infectious events than patients treated with adalim-
umab (OR: 5.99; 95% CI 1.55, 40.00). CONCLUSIONS: This study demonstrated 
that only half RA patients sustained their original biological therapy for more than 2 
years. Furthermore, RA patients who treatd with etanercept acquired higher risk of 
infectious events. However, it is still necessary to further ﬁ nd out reasons for discon-
tinuation and to explore the causality between biological agents and infectious events. 
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GASTROINTESTINAL AND CARDIOVASCULAR RISK OF NONSELECTIVE 
NSAIDS AND COX-2 INHIBITORS IN ELDERLY PATIENTS WITH KNEE 
OSTEOARTHRITIS
Turajane T
Police General Hospital, Bnagkok, Thailand
OBJECTIVES: To evaluate the risk for gastrointestinal (GI) events and 
cardiovascular(CV) events in patients >60 years with knee osteoarthritis using 
tNSAIDs or coxibs users. METHODS: A hospital-based retrospective cohort study 
was applied. Data on prescription drug (NSAIDs, celecoxib, etoricoxib) was obtained 
from June 2004 to June 2007 were included if they were aged >60 years. Patients with 
a history of gastrointestinal disease or heart disease were excluded. RESULTS: A total 
12,591 prescriptions from 1030 patients, an average of four prescriptions/patient/year, 
were screened—3982 (31.6%) prescriptions were for NSAIDs, 4426 (35.2%) were for 
celecoxib, and 4183 (33.2%) were for etoricoxib. The most common traditional 
NSAID prescribed was meloxicam (24%). The mean age of cohort was 69.6 years, 
with the majority being female (74%). Comparing celecoxib with NSAID use in 
logistic regression analysis, patients who received celecoxib were signiﬁ cantly less 
likely to suffer GI events than those who received NSAIDs; OR = 0.36 (95% CI 
0.21–0.63, P = 0.00). Similarly, etoricoxib was less likely to cause GI events than 
NSAIDs; OR = 0.52 (95% CI 0.28–0.98, P = 0.04). Comparing to patients aged under 
60 years, patients aged >70 years had a signiﬁ cantly higher chance of developing GI 
events, OR = 1.79 (95% CI 1.13–2.4) for patients aged 70–80 years and 3.36 (95% 
CI 1.78–5.81) for those aged >80 years. Drug exposure time, signiﬁ cantly increased 
the GI risks. For CV event, there were only three signiﬁ cantly associated with CV 
events-female (OR = 0.29, 95% CI 0.16–0.59, P = 0.00), age > 80 years (OR = 2.98, 
95% CI 1.57–4.23, P = 0.00), and drug exposure time (OR = 1.05, 95% CI 1.02–1.54, 
P = 0.00). CONCLUSIONS: Incidence of GI and CV events was lower for coxibs than 
for NSAIDs and celecoxib had a lower incidence than etoricoxib. Patients with 
advanced age and higher drug exposure time had a signiﬁ cantly. 
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THE RISK OF REFRACTURE ASSOCIATED WITH THE COMPLIANCE 
AND THE PERSISTENCE WITH BISPHOSPHONATE THERAPY IN 
TAIWAN
Su YJ1, Lin MJ1, Tsai IC1, Soong YK2
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OBJECTIVES: To elucidate the relationship of the risk of refractures to compliance 
and persistence with bisphosphonate therapy in Taiwan. METHODS: We conducted 
a retrospective cohort study based on claims database of Taiwan’s National Health 
Insurance (NHI) between 2003–2006. The study subjects included all new users of 
bisphosphonates. Compliance was estimated using a medication possession ratio 
(MPR), calculated as the total days of supply divided by the number of days between 
the ﬁ rst and last dispensing plus the days of supply of the last dispensing. Persistence 
with bisphosphonate therapy was deﬁ ned as continuous use, allowing for a reﬁ ll gap 
of 30 days. RESULTS: The refracture rates of the osteoporosis patients increased with 
time. The refracture rate was 5.15%, 7.36%, and 8.49% at the ﬁ rst, second, and third 
years, respectively. The refracture rate of patients with over 80% compliance was 
signiﬁ cantly lower than those with a compliance below 80% (P < 0.05). The study 
found that nearly half of the patients were noncompliant with therapy (MPR < 80%) 
at as early as 3 months, and only around 30% of the patients were adherent at 1 year. 
The results also showed that the risk of refracture increased for patients with MPR < 
80%, non-persistence, older patients and patients with comorbidities such as rheuma-
toid arthritis, diabetes mellitus or dementia. Patients with concomitant statin medica-
tion tended to have signiﬁ cantly lower refracture risks than those without. 
CONCLUSIONS: From the study, the compliance and persistence of Taiwanese 
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patients is poor. In addition, the study demonstrated that the risk of refracture is 
associated with the compliance and persistence with bisphosphonate therapy in 
Taiwan. The compliance and persistence issues for osteoporosis treatment warrant 
much more attention. 
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CHINA: RESULTS FROM 2009 NATIONAL HEALTH AND WELLNESS 
SURVEY
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OBJECTIVES: To assess comorbidity, quality of life (QOL), work/productivity loss, 
and medical resource utilization in patients with rheumatoid arthritis (RA). 
METHODS: Patients’ self-reported data were collected from 2009 National Health 
and Wellness Survey (NHWS). Survey samples represented major urban areas in 
China. QOL was measured by the physical component score (PCS) and mental com-
ponent score (MCS) of the Short Form-12 (SF-12) (mean score of 50 for general popu-
lation). Loss of work/productivity was measured by the validated Work Productivity 
and Activity Impairment (WPAI) instrument. Medical resource utilization was mea-
sured by health-care provider, emergency room (ER) visits and hospitalization in the 
past 6 months. Comparisons were made between respondents who suffer from RA 
(excluding psoriasis, psoriatic arthritis, or inﬂ ammatory bowel disease) versus respon-
dents without RA (non-RA group). RESULTS: Of the 13,307 survey respondents, 276 
(2.1%) were diagnosed with RA, and the average age was 46.6 years. There were 
more females in RA group (59.5%) versus non-RA group (50.7%). RA group reported 
more diagnosed comorbidities (insomnia 43%, hypertension 24.7%, migraine 24.1%, 
allergies 23.4%, arrhythmia 22.8%, gingivitis 22.5%, dermatitis 18.9%, osteoporosis 
16.9%, anemia 15.5%, bronchitis 13.9%, asthma 13.7%), lower mean scores of PCS 
(42.7 ` 48.5) and MCS (42.4 vs. 46.0), more patients visited health-care providers 
(83.3% vs. 56.3%), ER (48.5% vs. 18.9%) and hospitalized (25.0% vs. 7.0%) in the 
past 6 months compared to non-RA group. Also, RA group reported 37.8% work/
productivity loss (absenteeism and presenteeism) and 36.6% impairment in daily 
activity compared to 22.7% and 22.6% in non-RA group. All comparisons between 
RA and non-RA groups were statistically signiﬁ cant at P < 0.05. CONCLUSIONS: 
From the China NHWS results, RA patients suffer from impairment in quality of life, 
work/productivity loss, more comorbidities and use of medical services. The ﬁ ndings 
indicate there is still an unmet medical need in RA patients in China. 
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MICRO-COSTING OF JUDO-THERAPY CLINICS IN JAPAN—MULTI-
CENTERED COST ANALYSIS
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OBJECTIVES: In the Judo-therapeutic ﬁ eld, their costs are partly covered by National 
Health Insurance System via fee-for-service reimbursement, which does not necessarily 
reﬂ ect actual costs. Therefore, the actual situation of medical practice in Judo-therapy 
Clinics (bone-setting clinics) is analyzed by comparison between the actual costs cal-
culated by micro-costing methods and .reimbursement cost calculated by fee-for-
service system. METHODS: The basis of this study is a bidirectional evaluation of 
single medical intervention in terms of actual cost and reimbursed cost for single 
treatment with following methods: 1) All receipts are collected from the participating 
bone-setting clinics for a ﬁ xed period of time; 2) Along with collection of receipts, 
information on the medical interventions is recorded by region with regard to “how 
long” and “who” performed them; 3) The tentative cost of medical intervention is 
calculated based on the data in 2) above and the data of wage for the engaged persons. 
In other words, the tentative cost is calculated as the practitioner’s wage per unit time 
multiplied by the time consumed; 4) The cost-based amount of individual medical 
intervention is calculated by adding indirect costs (wage for other staff than practitio-
ner, cost for operation/maintenance of judo-therapy clinic) to the data in 3); and 5) 
Standard critical paths are made for several diseases, based on which medical expense 
for each therapy model is calculated in terms of both receipt-based amount and cost-
based amount, and a comparison of amount is made between them. RESULTS: 
Therapies in a total of 1646 regions were recorded, based on which a comparison was 
made using four diseases (lumbar sprain, neck sprain, femoral contusion, back contu-
sion) as models. The receipt-based medical expense was JPY9030 (US$100) for all 
diseases, while the cost-based medical expense widely varied from JPY22,057 to 
JPY22,950 (US$245 to US$255). CONCLUSIONS: There was a signiﬁ cant difference 
between the insurance beneﬁ t amount and the actual cost of medical intervention in 
judo-therapy. 
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OF OSTEOPOROTIC HIP FRACTURES AMONG THAI POST-
MENOPAUSAL WOMEN: A PILOT INVESTIGATION
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OBJECTIVES: Facing scarce data in Thailand on hospital costs of osteoporotic frac-
tures, we examined repeated fractures and hospital costs incurred over 1 year from a 
primary osteoporotic hip fracture hospitalization occurred in postmenopausal women 
with or without comorbidities at Bumrungrad International Hospital in Bangkok. 
METHODS: Hospital admissions for primary hip fracture coded ICD-10 S 72.1 in 
post-menopausal women, aged 55 or older, were collected from January 2007 to 
January 2009. The hip fracture comorbidities considered were hypertension, type 2 
diabetes, cardiovascular disease and their combinations. The repeated fractures within 
6 or 12 months after ﬁ rst admission were documented. All direct medical costs were 
retrieved from the hospital database looking at 1-year follow-up period. Statistical 
analysis employed unpaired t-test, Mann–Whitney U test and multivariate analysis for 
comparison of outcomes, costs and correlations to comorbidities. RESULTS: A total 
of 59 hospital admissions for diagnosed osteoporotic primary hip fracture in post-
menopausal women were screened. Patients’ mean age (SD) was 74.6 (7.7) years old, 
the mean hospital follow-up (SD) was 246.7 (77.5) days and the mean hospitalization 
duration (SD) was 17.0 (12.2) days. Patients at screening with and without comorbidi-
ties had similar characteristics including the types of fractures. The group with comor-
bidities was at higher relative risks of repeated fractures at 6 and 12 months follow-up 
compared to the group without comorbidities (1.13 vs. 0.91, P = 0.016; 1.10 vs. 0.94, 
P = 0.273, respectively) with consequently higher health-care utilization cost with 
564,300 THB/patient/year versus 374,200 THB/patient/year, P = 0.043. The cost of 
all type drugs for both groups was only 8–10% of the total illness cost. CONCLU-
SIONS: In osteoporotic post-menopausal women admitted at hospital for primary hip 
fracture, comorbidities increased risks of repeated fractures hospitalization as well 
as hospital costs. The cost of drugs was marginal among hospital costs of 
osteoporosis. 
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A COST-EFFECTIVENESS ANALYSIS OF OSTEOPOROSIS TREATMENT 
FOR FRACTURE PREVENTION IN POSTMENOPAUSAL THAI WOMEN: 
A COMPARISON OF SEVEN TREATMENT OPTIONS
Pongchaiyakul C1, Songpattanasilp T2, Taechakraichana N3
1Khon Kaen University, Muang, Khon Kaen, Thailand; 2Phramongkutklao Hospital and College 
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OBJECTIVES: To evaluate the cost-effectiveness of bisphosphonates (alendronate, 
risedronate, ibandronate, zoledronic acid), raloxifene, calcitonin and strontium 
ranelate, with a combination of calcium and Vitamin D as comparator, for the preven-
tion of osteoporosis-related fractures in Thai post-menopausal women. METHODS: 
A Markov state transition model with 1-year cycle length was designed to simulate 
the cost-effectiveness of seven osteoporosis treatment interventions, compared with 
calcium and vitamin D, in Thai post-menopausal women aged 50–70 years. The model 
health states were categorized as osteopenia/no fracture, hip fracture, vertebral frac-
ture, post-hip fracture, post-vertebral fracture and death. Treatment effects were 
obtained from published literature. The analysis was conducted using a societal per-
spective and included direct medical, direct nonmedical and indirect costs. Uncertainty 
was investigated by a probabilistic Monte Carlo simulation. Treatment outcomes were 
measured in terms of number of fractures avoided, number of life-years gained and 
quality-adjusted life-years (QALY) gained. Cost-effectiveness was deﬁ ned as an ICER 
of less than 300,000 Baht (an incremental cost of ≤300,000 Baht for an outcome of 
no fracture for 1 year). RESULTS: 1) For patients with no prior fracture (primary 
prevention), zoledronic acid is cost-effective at ≥65 years, alendronate, risedronate and 
ibandronate at ≥70 years. 2) For patients with prior vertebral fracture (secondary 
prevention), zoledronic acid is cost-effective at ≥50 years, alendronate, risedronate and 
ibandronate at ≥55 years, raloxifene and strontium ranelate at ≥60 years; and 3) For 
patients with prior non-vertebral fractures, zoledronic acid is cost-effective at ≥60 
years, alendronate at ≥65 years, and risedronate and ibandronate at ≥70 years. CON-
CLUSIONS: Zoledronic acid, followed by other bisphosphonates, is the most cost-
effective treatment option for both primary and secondary fracture prevention in Thai 
postmenopausal women with osteoporosis. These ﬁ ndings should be implemented in 
the government policy for selecting appropriate anti-osteoporotic drugs and reim-
bursement support strategy for Thai postmenopausal women with osteoporosis. 
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OBJECTIVES: We sought to determine, from the Australian health-care perspective, 
the cost-effectiveness of the bisphosphonate risedronate, relative to placebo, in pre-
venting vertebral fractures among patients with corticosteroid-induced osteoporosis. 
METHODS: A decision-analytic Markov model was developed to simulate the onset 
